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Background
For secondary prevention of fatal and non-fatal cardio-
vascular events, benefits of aspirin (ASA) are well defined,
and form the basis for current clinical practice [1–4]. In
patients without a history of cardiovascular diseases
(CVD), in contrast, the picture is not clear: several meta-
analyses [5, 6] and the individual data meta-analysis of
the antithrombotic trialists’ (ATT) collaboration [7] show
that the efficacy of ASA in reducing the risks of acute
myocardial infarction (MI) and ischemic stroke does not
outweigh the associated increased risk of bleeding. The
conflicting recommendations from guidelines panels reflect
this uncertainty [3, 8, 9]. After the publication of ATT
study in 2009 [7], three more randomized controlled
studies (RCT) evaluating the use of ASA in primary pre-
vention were published [10–12]. Recently, three nearly
contemporaneous meta-analyses [13–15] combined old and
newest trials’ results.
Summary
We discuss three meta-analyses published between January
2011 and 2012 that evaluated trials in primary cardiovas-
cular prevention and involved a randomized comparison of
ASA versus placebo or control [13–15].
The first was carried out by Berger et al., who searched
electronic databases (MEDLINE, the Cochrane Central
Register of Controlled Trials, and EMBASE) for RCTs
published up to 2011 [13]. The occurrence of a major
cardiovascular event (MCE), i.e. non-fatal MIs, non-fatal
strokes, all-cause and cardiovascular mortality, was chosen
as primary outcome. As primary safety outcomes, the
authors included major bleedings as defined by each study.
All outcomes were analysed using the data reported in the
original publications. Random effect meta-analysis was
executed, using risk ratio (RR) as efficacy measure. Sen-
sitivity analysis was performed and specific subsets of
studies were analysed (removing one by one trials enrolling
patients with diabetes or subclinical atherosclerosis and
those including extended or controlled release aspirin).
Meta-regression was applied to evaluate potential effect
modifiers (year of study publication, baseline cardiovas-
cular risk, mean age and sex of trial’s participants, and dose
of ASA). Potential publication biases were examined by
constructing a funnel plot. Nine prospective randomized
trials involving 102,621 participants (52,145 allocated to
aspirin, 50,476 to placebo/control) were identified for
inclusion and meta-analysed.
The same nine trials were incorporated in the meta-
analysis by Raju et al. [14]. Medline, Cinahl, Embase and
the Cochrane Library databases were sought up to May
2010, bibliographies of journal articles were hand-sear-
ched and experts were contacted to identify unpublished
studies. Raju et al. considered the following outcomes
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(accepting primary trials investigators’ definition): all-
cause mortality, cardiovascular mortality, major cardio-
vascular events (cardiovascular mortality, non-fatal MIs
and non-fatal strokes), fatal or non-fatal MIs, fatal or non-
fatal all-cause strokes, ischemic and haemorrhagic strokes,
major and gastrointestinal bleedings. A risk of bias
assessment using criteria adapted from the Cochrane
Handbook on Systematic Reviews of Interventions [16]
(proper generation of allocation sequence, proper con-
cealment of the allocation sequence, blinding of partici-
pants, investigators, and outcome assessors, completeness
of follow-up) was performed. Risk ratios (RR) were
pooled with a random effect model and potential sources
of statistical heterogeneity were explored, considering
effect sizes related to year of publication of the study,
cardiovascular baseline risk, mean age and sex of partic-
ipants, and dose of ASA. Sensitivity analysis was per-
formed excluding studies of lower quality (open label or
with an incomplete follow-up), trials using higher doses of
ASA ([150 mg/day), and those completed before 2000
(when different co-therapies for cardiovascular risk factors
were supposed to be used). A total of 100,076 patients
(50,868 in aspirin arm and 49,208 in placebo/control
group) were included, because warfarin arms from facto-
rial TPT study were excluded.
Finally, Seshasai et al. [15] searched PubMed and
Cochrane Library electronic databases up to June 2011 for
primary prevention randomized trials that included at least
1,000 participants, had at least 1-year of follow-up,
recorded as main end-point CVDs and provided details of
bleeding events. Primary efficacy end-point considered in
the meta-analysis was total coronary heart diseases (CHD),
whereas subtypes of vascular diseases, total CVD events,
cause-specific deaths and all-cause mortality were sec-
ondary outcomes. As composite primary safety end point
clinically ‘‘nontrivial’’ bleeding events were chosen,
including fatal bleedings from any site, cerebrovascular or
retinal bleedings from hollow viscus, bleedings requiring
hospitalization or transfusion or study-defined major
bleedings regardless of source. Seshasai et al. also analysed
the effect of ASA in cancer prevention, but we decided not
to report data, as we commented on the topic in a previous
article [17]. The quality of the studies was evaluated using
a Delphi scoring system based on the adequacy of ran-
domization, allocation concealment, balance between
groups at baseline, a priori identification of inclusion cri-
teria, presence or absence of blinding, use of intent-to-treat
analyses and reporting of point estimates and measures of
variability. Potential publication bias was investigated with
the use of funnel plots and by the Egger test. Combined
odds ratios (ORs) were obtained by a random effects meta-
analysis. Subgroup analyses considering participants’
characteristics (mean age, percentage of men, smokers and
diabetic participants, mean cholesterol levels and systolic
blood pressure, dose of ASA administered) and sensitivity
analysis excluding studies published before 2000, per-
formed in non-Western population or exclusively in dia-
betics, people with peripheral arterial disease or health
professionals were carried on. Seshasai et al. retrieved the
nine randomized prevention trials analysed in the two
previous meta-analyses. Like in Raju et al. [14], 102,621
patients (52,145 and 50,476 in aspirin and control group,
respectively) were included.
Overall, the population studied was clinically heteroge-
neous. Original trials considered different cardiovascular
risk profiles and administered different ASA doses (from
100 mg every other day to 500 mg daily). Three of the nine
studies did not enroll women [18–20], whereas another one
exclusively comprised them [12]. Two trials recruited only
patients with diabetes mellitus [10, 12], one enrolled
patients with a negative anamnesis for symptomatic car-
diovascular diseases but with an ankle-brachial index\0.95
[11], and, finally, two studies included a small proportion of
participants (\5 %) with a history of ischemic heart disease,
stroke or transient ischemic attack [18, 19–21].
After carefully reading the description of the outcomes,
we decided to classify similar end-points from single meta-
analyses with a same label. The results of the three sys-
tematic reviews are reported in Table 1; they look roughly
alike. The little gaps among the data are due to different
populations and follow ups considered. Overall, ASA in
primary prevention of cardiovascular diseases decreases
the risk of total CVD events, but it mainly increases the
possibility of major bleedings and is not associated with a
significant reduction in all-cause or cardiovascular mor-
tality (Table 1). No substantial results’ modification was
retrieved with subgroup analysis or meta-regression. Sen-
sitivity analysis showed that there was no difference when
(1) subjects with diabetes, asymptomatic PAD, or health-
care professionals or (2) studies considering a dose of
aspirin major than 150 mg day or (3) studies conducted
before 2000 were excluded. Finally, the results are similar
using fixed- or random-effect model.
Seshasai et al. [15] evaluated the absolute benefit versus
adverse effects risk of ASA treatment according to the
absolute event rates in the placebo arms. Both the net
benefit related to the reduction of CVD events risk and the
frequence of nontrivial bleeding events increased as abso-
lute CVD event rates at baseline raised, but the net CVD
benefit exceeded the bleeding risk at higher baseline CVD
event rate. Statistical heterogeneity (quantified with Hig-
gins test [22] and expressed as I2) was relevant only for few
outcomes (66 % for myocardial infarction and 37 % for
gastrointestinal bleeding) [13, 14].
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In summary, Berger et al. [13] commented on their work
stating that the decision to use aspirin for MCE primary
prevention remains a complex issue, requiring careful
consideration. They reported for total CVD events an NNT
of 253 and for major bleedings an NNH of 261 with a mean
follow-up period of 6.9 years. Raju et al. [14] described the
results as relative risk reduction (RRR) without considering
the statistical significance of the data or their CIs, and
declared that long-term treatment with ASA reduces all-
cause mortality (RRR 6 %) and MI (RRR 17 %). Finally,
Seshasai et al. [15] reported an NNT for total CVD events
of 120 and an NNH for major bleedings of 73 with a mean
follow-up period of 6.0 years. They concluded that,
because the benefit of aspirin treatment is accompanied by
a significant increase in the possibility of bleeding, further
studies are needed to identify subsets of participants having
favourable risk to benefit ratio or involving patients at
higher risk.
Strengths of the studies
• The three meta-analyses address a debated and clini-
cally relevant topic; it is well known that cardiovascular
diseases are the first cause of death in developed world.
• Evaluation of benefit versus risk is performed.
• Sources of heterogeneity are assessed and sensitivity
analysis is carried on.
• Raju et al. [14] and Seshasai et al. [15] report a clear
search strategy and study selection process.
Weaknesses of the studies
• We are aware that sensitivity analysis show the
robustness of results removing trials at higher risk of
bias, but comparisons in the studies included in meta-
analyses could be questionable. Seshasai et al. [15] and
Berger et al. [13] analyze all data from TPT trial [18],
including also those from the aspirin or placebo asso-
ciated with warfarin arms. In that study anticoagulation
level obtained with warfarin is low (mean INR around
1.5) but the group treated with warfarin shows a risk of
major gastrointestinal bleedings significantly higher
than placebo arm.
• In the work by Berger et al. [13] the search strategy to
identify studies is not shown: so they performed a meta-
analysis without describing in detail the systematic
review process.
• Raju et al. [14] report relative risk reduction marking it
as significant, but they don’t calculate any statistical
difference test or confidence intervals nor did they relay
subgroup results.T
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Question marks
• A trend towards a reduction in all-cause mortality is
observed: although the effect is modest and statistically
non-significant (-6 %, 95 % IC 0.88–1.00), consider-
ing the importance of the outcome and virtual benefit of
ASA further investigations are mandatory to clarify this
pivotal issue.
• The population enrolled in primary RCTs are hetero-
geneous, as it spans from healthy male doctors to
patients with subclinical atherosclerosis, and finally to
general population, and also CVD baseline risks are
different. Relative risk or odds ratio permit to compare
different risk population, but in this situation NNT
should be calculated according to the different baseline
risks. Thus, it may be helpul to use individual data to
evaluate NNT and NNH in different subgroups (e.g.
stratifying by CVD risk, age, co-morbidity) to identify
the groups where the occurrence of adverse events is
minimal.
• Three of the nine studies analysed included patients
with low ankle brachial index. The detection of
subclinical vascular lesion in asymptomatic people is
a predictive factor of cardiovascular disease [23]. Even
if the exclusion of these studies does not affect the
results (as declared by the authors), we wonder whether
they should be included in the meta-analyses.
Sponsorships
• Berger’s research was supported by Astra Zeneca [13].
Raju et al. [14] and Seshasai et al. [15] did not report
funding for the study.
Clinical bottom line
• The available evidence doesn’t support the routine use
of ASA for primary prevention of CVD in general
population. The benefits in reducing CVD are almost
perfectly equivalent to the adverse effect. The risk-
benefit ratio should be weighed in every subject. In fact,
it is reasonable to speculate that patients at moderate-
high risk for CVD (i.e. above 1 % CVD event rate per
year) and low bleeding risk can benefit from the use of
ASA. This therapeutic strategy should be confirmed by
further investigations.
Conflict of interest None.
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